Atıf Formatları
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

C. Erol Et Al. , "Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group," Journal of cancer research and therapeutics , vol.18, 2022

Erol, C. Et Al. 2022. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. Journal of cancer research and therapeutics , vol.18 .

Erol, C., Nahit Sendur, M. A., Bilgetekin, I., Garbioglu, D. B., Hamdard, J., Akbas, S., ... Hizal, M.(2022). Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. Journal of cancer research and therapeutics , vol.18.

Erol, Cihan Et Al. "Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group," Journal of cancer research and therapeutics , vol.18, 2022

Erol, Cihan Et Al. "Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group." Journal of cancer research and therapeutics , vol.18, 2022

Erol, C. Et Al. (2022) . "Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group." Journal of cancer research and therapeutics , vol.18.

@article{article, author={Cihan Erol Et Al. }, title={Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group}, journal={Journal of cancer research and therapeutics}, year=2022}